OBJECTIVE:
In a reverse syphilis screening algorithm, a treponemalspecific test such as a chemiluminescent immunoassay (CIA) identifies pregnant women with CIA+/RPR-results which may represent high or low infectivity. The CIA signal-to-cutoff (S/Co) ratio, a measure of signal strength relative to a calibrated laboratory threshold, is reactive (positive) at a threshold level of 1. We evaluate the utility of CIA S/Co ratio as an adjunct to reactive plasma reagin (RPR) status in characterizing maternal infectivity and risk to the fetus. STUDY DESIGN: A prospective, observational study of reverse syphilis screening was conducted. Women were screened with a CIA at the initial visit, 32 weeks, and delivery. Reactive CIA was reflexed to RPR; particle agglutination assay (TPPA) was performed for CIA+/RPRresults. Relative CIA S/Co ratios and neonatal outcomes were compared among 4 groups: 1)CIA+/RPR+, 2)CIA+/RPR-/TPPA+ (confirmed prior treatment), 3)CIA+/RPR-/TPPA+ (no prior treatment or syphilis history), and 4)CIA+/RPR-/TPPA-(false positive CIA). RESULTS: Eighty-five women had reactive CIA, including 39% RPR+ and 61% RPR-(15% TPPA-, and 85% TPPA+). Maternal demographic characteristics are shown in Table 1 . Sonographic findings of congenital syphilis occurred exclusively among CIA+/RPR+ women. Of delivered neonates, none showed physical signs of congenital syphilis; RPR+ neonates were born exclusively to CIA+/ RPR+ women. Mean S/Co ratio was significantly higher for CIA+/ RPR+ women in Group 1 compared with all other groups (Figure 1 ). There was no difference in S/Co ratio among CIA+/RPR-/TPPA+ women in Groups 2 and 3 (p¼0.08). No adverse neonatal outcomes were found among CIA+/RPR-/TPPA+ women in groups 2 or 3, regardless of maternal treatment history. CONCLUSION: When using a reverse syphilis screening algorithm, a higher CIA S/Co ratio and RPR+ status signifies higher maternal infectivity and risk for congenital syphilis. Lower S/Co ratio and RPR-status suggest low maternal infectivity and risk for congenital syphilis. Obstetric and neonatal providers can be reassured that CIA+/RPR-women with low CIA S/Co ratio pose low risk to the fetus regardless of treatment history. Hadassah Medicial Center, Jerusalem, Israel OBJECTIVE: To investigate the incidence, risk factors, clinical course and outcomes of peripartum group A streptococcus (GAS) infection. STUDY DESIGN: A retrospective 13-year cohort study of cultureproven puerperal GAS infection among 140,429 women who delivered at two university hospitals, serving heterogeneous, multicultural, urban and rural populations. RESULTS: Of 124 women diagnosed with peripartum GAS infection, 115 (93%) were in the puerperium, an incidence of one postpartum GAS infection per 1,220 births (0.08%). A multivariate analysis showed primiparity and cesarean delivery to be independent protective factors against GAS infection (P¼0.04 and P¼0.009, respectively). The predominant manifestations were fever and abdominal tenderness, appearing after a median of four days postpartum. Thirty (24%) patients had severe GAS infections, including one or more of the following: bacteremia (n¼19), septic shock (n¼10), intensive care unit admission (n¼11) and sepsis-related complications (n¼17). All were treated with beta-lactams and most (n¼104, 84%) received clindamycin. Only 4 (3%) required surgical intervention; the rest fully recovered with conservative medical treatment including antibiotics. No recurrences, maternal deaths or neonatal complications were noted. CONCLUSION: Peripartum GAS infection is not rare; it lacks specific signs and still carries significant morbidity. Primiparity, a presumable surrogate for diminished exposure to children and thus less GAS carriage, and cesarean delivery in which perioperative antibiotic prophylaxis was uniformly given, appear as protective factors against GAS infection. This hints to the importance of community-acquired GAS and the potential benefit of chemoprophylaxis. These findings may support shifting efforts from infection-control oriented nosocomial investigations to screening and prophylaxis policies.
